logo

For the Inventor, By the Inventor

Jersey City, NJ, United States of America

Scynexis, Inc.


USPTO Granted Patents = 18



Trademarks = 3

Forward Citations = 51

Loading Chart...
Loading Chart...

28 inventors (with patents filed for the assignee):

goldMedal David Renwick Houck (8 out of 8 patents)

silverMedal Michael Robert Peel (4 out of 8 patents)

bronzeMedal Yi Zhang (3 out of 16 patents)

4.  Keqiang Li (3 out of 5 patents)

5.  Ahmed Mamai (3 out of 5 patents)

6.  David A Angulo Gonzalez (2 out of 2 patents)

7.  Andrew Scribner (2 out of 12 patents)

8.  Weiming Fan (2 out of 9 patents)

9.  Hans Georg Fliri (2 out of 2 patents)

10.  James M Balkovec (2 out of 47 patents)

11.  Frances A Bouffard (2 out of 18 patents)

12.  Phieng Siliphaivanh (1 out of 32 patents)

13.  Rebecca A Chmielowski (1 out of 2 patents)

14.  Hao Liu (1 out of 3 patents)

15.  Dongfang Meng (1 out of 23 patents)


18 patents:

1. 11534433 - Antifungal agents with enhanced activity in acidic pH (2022-12-27),
2. 11110102 - Antifungal agents used in combination (2021-09-07),
3. 10927142 - Salts and polymorphs of SCY-078 (2021-02-23),
4. 10370406 - Salts and polymorphs of SCY-078 (2019-08-06),
5. 10174074 - Salts and polymorphs of SCY-078 (2019-01-08),
6. 9090671 - Macrocyclic peptides (2015-07-28),
7. 8674087 - Processes for isolation and purification of enfumafungin (2014-03-18),
8. 8551952 - Methods for the treatment and prevention of ocular disorders (2013-10-08),
9. 8536114 - Macrocycles (2013-09-17),
10. 8329658 - Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection (2012-12-11),
11. 8222255 - Antifungal agents (2012-07-17),
12. 8188052 - Method for the treatment and prevention of ocular disorders (2012-05-29),
13. 7863465 - Antifungal agents (2011-01-04),
14. 7754685 - Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection (2010-07-13),
15. 7718767 - 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection (2010-05-18),
Scynexis, Inc. is a biotechnology company that develops and delivers innovative therapies for difficult-to-treat and often life-threatening infections. The company focuses on developing novel anti-infectives to address unmet medical needs. Scynexis utilizes its proprietary drug discovery platform to develop a pipeline of potential drug candidates. With a commitment to improving patients' lives, Scynexis aims to provide effective treatments for serious infections.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
18 Patents

#11 in Jersey City, NJ

#672 in New Jersey

#17,414 in US

#33,185 in the World

...
Jersey City, NJ, United States of America

Scynexis, Inc.

Forward Citations = 51

28 inventors:

goldMedal David Renwick Houck (8 out of 8 patents)

silverMedal Michael Robert Peel (4 out of 8 patents)

bronzeMedal Yi Zhang (3 out of 16 patents)

4.  Keqiang Li (3 out of 5 patents)

5.  Ahmed Mamai (3 out of 5 patents)

Please report any incorrect information to support@idiyas.com
Loading…